Evonik Opens New Facility for Pharmaceutical Lipids in Germany

Evonik has opened a new GMP facility to manufacture lipids for advanced pharmaceutical drug delivery applications. The lipid facility is located at the company’s site in Hanau, Germany and provides customers with quantities of lipids needed for clinical and small-scale commercial manufacturing.

According to the company, the new building complements Evonik’s existing lab and commercial production capabilities to meet the needs of partners at every stage of development and commercialization.

The types of lipids that can be produced at Evonik’s lipid facility will serve a broad range of RNA and gene therapies such as infectious disease control, cancer immunotherapy and protein replacement therapies.

With particle engineering and purification capabilities, including chromatography, the lipid launch facility can support customers with production of all types of custom and proprietary lipids, including PEGylated lipids, phospholipids, and ionizable cationic lipids.

“We are excited about the timely opening of our new facility. Our customers benefit from our expanded integrated portfolio of System Solutions for advanced drug delivery, enabling the development of novel nucleic acid therapies and other medicines of the future,” said Thomas Riermeier, head of Evonik’s Health Care business.

“Our offering allows customers to obtain high-quality GMP material consistent with larger scale production, enabling a seamless path for scale up – allowing our partners to move quickly in this fast-paced development space,” said Paul Spencer, head of Drug Delivery & Products at Evonik’s Health Care business.

The opening of the lipid launch facility is the latest in a series of investments by Evonik in lipid manufacturing for RNA and gene therapies. Last year, the company announced a triple-digit million-dollar joint investment with the U.S. Government to build a new lipid production facility at its U.S. site in Tippecanoe, IN.